On Demand 2025 Friday PM General Sessions

This course contains the following sessions from Friday's afternoon program:

  • ABAI - Let’s Talk CAP Articles, Continuing Certification Comparison and Professionalism
  • Practical Approaches to Drug Hypersensitivity: Managing Diverse Populations and Real-World Challenges
  • EAACI – From Biomarkers to Patient Diagnosis
  • Updates in Eosinophilic Esophagitis

Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 5.5 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Target Audience

Medical professionals who treat patients with allergic and/or immunological conditions:

  • Practicing allergist/immunologists
  • Allergy/immunology Fellows-in-Training
  • Physician assistants
  • Nurses and advanced practice nurses
  • Allied health professionals
  • Primary care physicians
  • Other medical professionals

Learning Objectives

Upon completion of this session, participants should be able to:

  • Understand the role practicing allergist-immunologists play in CAP assessments to best meet the needs and interests of diplomates.
  • Identify unifying and differentiating continuing certification program requirements between ABAI and other American Board of Medical Specialties Certifying Boards.
  • Understand emerging professionalism expectations and requirements for the practicing allergist-immunologist.
  • Identify effective teaching strategies for application of the PEN-FAST tool and antibiotic stewardship as well as evaluate a new Allergy and Immunology focused curriculum upon completion of this teaching session. Review essential tools and strategies for establishing and running a drug allergy clinic, including patient assessment, diagnostic testing, and developing individualized management plans to enhance clinical practice and patient outcomes.
  • Discuss the principles and best practices for antibiotic delabeling in special populations such as pediatric patients, pregnant women, and bone marrow transplant recipients, with an emphasis on safety, efficacy, and patient-centered decision-making.
  • Explain practical approaches to diagnosing and managing NSAID allergy in the outpatient setting, including distinguishing between true hypersensitivity and intolerance, and with special consideration for challenging situations and specific NSAID allergy phenotypes.
  • Identify the challenges in classifying allergic reactions to drugs.
  • Classify allergic reactions to drugs according to clinical symptoms (phenotype) and chronology.
  • Recognize the mechanisms involved in allergic reactions and examine the role of endotypes in allergic reactions and how endotypes can influence the clinical presentation and management of allergic reactions to drugs. Understand the distinct behaviors of drugs as haptens. Explore diagnostic and therapeutic approaches for drug allergic reactions based on the mechanisms involved. Enunciate the recommendations and explain the underlying evidence for best practice in diagnosis and management of food allergy.
  • Appraise the latest diagnostic and monitoring tools for EoE.
  • Develop strategies for inducing remission in EoE and learn how novel data sets may help simplify future treatment algorithms.
  • Gain practical knowledge for optimizing patient care while navigating challenging cases of EoE.
Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months. The ACCME defines a “ineligible company” as companies whose primary business is producing, marketing, selling, re-selling, or distributing health care goods or services, used by or on patients. Examples of such organizations include: 
 
•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers
  
The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.
Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.
Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All identified relevant financial relationships have been mitigated.

Course summary
Available credit: 
  • 5.50 AMA PRA Category 1 Credit™
  • 5.50 Attendance
  • 5.50 CBRN
Course opens: 
11/24/2025
Course expires: 
12/07/2028
Part of: 
On Demand ACAAI 2025 Annual Scientific Meeting
Rating: 
0

Michael R. Nelson, MD, PhD, FACAAI
Theodore M. Freeman, MD, FACAAI
Michael R. Nelson, MD, PhD, FACAAI
Jay A. Lieberman, MD, FACAAI
Catherine Ye, MD
Ana Maria Copaescu, MD, PhD
Anna R. Wolfson, MD, FACAAI
Lily Li, MD
Jason Trubiano, PhD
André Moreira, MD, PhD
Jolanta Walusiak-Skorupa, MD, PhD
Alexandra Santos, MD
Yamen Smadi, MD
Melanie A. Ruffner, MD, PhD, FACAAI
Jonathan M. Spergel, MD, PhD, FACAAI

Available Credit

  • 5.50 AMA PRA Category 1 Credit™
  • 5.50 Attendance
  • 5.50 CBRN
Please login or create an account to take this course.